The myelodysplastic syndromes (MDS) are a diverse group of disorders of the haemopoietic stem cells characterised by ineffective and dysplastic haematopoiesis in one or more cell lines (Tricot et al., 1986) . Using conventional cytogenetic techniques about half of all MDS patients show clonal chromosomal abnormalities (Heim & Mitelman, 1986 ; Second International Workshop on Chromosomes in Leukaemia, 1979) , the most frequent cytogenetic abnormalities being partial or complete loss of chromosome 5 or 7, and trisomy 8. The presence of specific lesions like monosomy 7 and complex karyotypic abnormalities are associated with a higher risk of transformation to acute leukaemia (Michiels et al., 1986; Borgstrom, 1986; Todd & Pierre, 1986) .
For an adequate cytogenic analysis a satisfactory number of high quality mitoses are needed and this may not always be technically feasible. Another drawback to cytogenic analysis is that it is not possible to determine the lineage of cells analysed. Hence techniques are now being developed for the detection of chromosomal loss by DNA analysis which will complement standard cytogenetics. These methods depend on restriction fragment length polymorphism (RFLP) analysis to differentiate the two chromosomal homologues, each RFLP allele being derived from one of the two chromosomes. This type of analysis is informative if constitutional DNA displays heterozygosity for a particular RFLP, so that loss of one of these alleles in the tumour DNA indicates chromosomal loss (Koufos et al., 1984; Orkin et al., 1984; Reeve et al., 1984; Fearon et al., 1984) .
The majority of RFLPs are due to site polymorphisms with only two possible alleles caused by the presence or absence of the restriction enzyme cleavage site. For such polymorphisms at least 50% of individuals are homozygous for one allele and hence uninformative. The problem may be overcome by using several DNA probes for a particular chromosomal region in the hope that the patient will be heterozygous for at least one of the RFLPs. However, an alternative approach is to use a single tandem-repetitive DNA probe specific for a hypervariable chromosomal locus. Such probes detect many different alleles at a particular locus (the size of the allele varies with the number of copies of the repeating unit) with the majority of individuals being heterozygous at such loci. We demonstrate the feasibility of this approach in a study of chromosomal 7 loss in MDS using a hypervariable DNA probe, pAg3 which has been localised to 7q33-qter (Wong et al., 1986; (Bennett et al., 1982) . All peripheral blood leucocytes and bone marrow specimens were obtained at presentation prior to any cytotoxic chemotherapy and whenever clinically indicated, thereafter. In addition, where possible 15-20 hair root follicles as a source of constitutional DNA (Pilkington et al., 1987) were also obtained at the time of bone marrow sampling. Peripheral blood samples were taken from 58 normal healthy British volunteers as a control group. DNA analysis DNA was isolated from the peripheral blood leucocytes, bone marrow cells and hair root follicles as described (Old & Higgs, 1983; Gill et al., 1985) . DNA (3 jg) was digested with the restriction enzyme HinfI under conditions recommended by the manufacturers (Boehringer, Mannheim). The resultant DNA fragments were separated by electrophoresis in a 0.8% agarose gel and then transferred to a nylon membrane (Amersham, Hybond-N) by Southern blotting. When available, DNA from peripheral blood leucocytes, bone marrow cells and hair roots from each patient were electrophoresed in adjacent tracks.
The plasmid pAg3 was a subclone in pUC 13, containing a large hypervariable DNA fragment isolated from a human DNA fingerprint as described previously (Wong et al., 1986) . The probe pAg3 has been localised by somatic cell hybridisation and in situ hybridisation to chromosome 7 in the region 7q33-qter (Royle & Jeffreys, unpublished data). The DNA probe was a 7.1 kb Sau3A insert from pAg3, containing -171 tandem repeats of a 37 bp sequence plus 747 bp flanking DNA. Since it also contains the beginning of an Alu element, human competitor DNA was included in the hybridisations using this probe. Subsequently a 6.5kb AluI insert, without the Alu element, was used as a hybridisation probe and the human competitor DNA was omitted from the hybridisation. The probes were labelled to high specific activity by random hexanucleotide priming (Feinberg & Vogelstein, 1983) and hybridisation was carried out at 65°C as described (Old & Higgs, 1983 Marked difference in relative hybridisation intensities between the two pAg3 alleles was not observed in any of the 54 normal individuals heterozygous for this locus. In the majority of MDS patients the two plg3 alleles were of equivalent intensity (Figure 1 ). However, in ten cases the hybridisation signal of one of the two allelic bands was found to be much weaker indicating a loss in part or whole or a reduplication of one of the two chromosome 7 homologues. Details of the cytogenetic analysis in these ten patients are shown in Table I Figure 2 Loss of heterozygosity at pAg3 locus on chromosome 7 in ten MDS patients. DNA was digested with HinfI and hybridised to the pAg3 probe. The patients' initials are shown above the blots and correspond to details given in Table I ; lanes N represent normal individuals. The source of DNA is as indicated; PB -peripheral blood, HR -hair root, BM -bone marrow, trans BM -BM taken during transformation of disease, pres BM -BM at presentation of disease, rem BM -BM at remission of disease. In all the ten patients there is marked reduction in hybridisation intensity of one of the pAg3 allelic bands in tumour DNA. Note that in patient SH trans BM represents BM a, b and c taken at consecutive times during transformation of disease. The marked difference in hybridisation signal between the two pAg3 alleles in tumour DNA of patients FH, MB and RT was confirmed by hybridisation of pAg3 to Alul-digested DNA where changes occurred in bands of similar sizes as expected since (Kere et al., 1987) in which three DNA probes which detect site polymorphisms (i.e. each detecting only 2 possible alleles) were used. We present a more efficient method for the detection of loss of chromosome 7 using a single chromosome 7 specific hypervariable DNA probe (pAg3). The heterozygosity rates in both the normal individuals and the MDS patients were extremely high, demonstrating the validity of this approach in the distinction of the chromosomal homologues. An added advantage of using a hypervariable DNA probe is that the RFLP is usually detectable using a variety of restriction enzymes unlike site polymorphisms where the RFLP is only present for a particular restriction enzyme cleavage site. The practical implication is that filters can be readily rescreened with other hypervariable region probes for other chromosomal losses.
pAg3 is localised to 7q33-qter and, therefore, is useful for the detection of monosomy 7, complete or partial deletion of 7q or development of homozygosity by mitotic recombination in 7cen-7q33. Interstitial deletions of chromosome 7 will be detected if the segment specific to this probe is involved. Ten of the 118 (9%) MDS patients who were informative for the pAg3 locus showed marked, unequal intensities of the two allelic bands. This result is in keeping with the numbers of monosomy 7 abnormalities detected in MDS in several studies (Heim & Mitelman, 1986; Michiels et al., 1986; Yunis et al., 1986; Jacobs et al., 1986 ). In fact the ten patients who showed loss of one of the chromosome 7 homologues by RFLP analysis include all five patients demonstrated to have full or partial monosomy 7 by cytogenetic analysis. There were no cases of monosomy 7, demonstrated cytogenetically, which was not detected by DNA analysis. It is interesting that the two patients, JC and NW, with secondary MDS in this series both had monosomy 7. In five patients chromosomal 7 loss demonstrated by DNA analysis was not demonstrated by cytogenetic analysis. This could be because many patients with myelodysplasia have poor proliferation of the abnormal clone and metaphases may be obtained only from the residual normal population. Since the probe is localised to 7q33-qter, it is also possible that in these cases there is a submicroscopic deletion of the tip of 7q which is not obvious cytogenetically.
We have shown that it is readily possible to screen a large number of MDS patients for a particular chrosomal loss using a single hypervariable DNA probe. The isolation of an increasing number of hypervariable DNA probes specific for other chromosomal regions (Wong et al., submitted) 
